Department of Rheumatology, First Affiliated Hospital of Anhui College of Traditional Chinese Medicine, Hefei, China.
Chin J Integr Med. 2011 Oct;17(10):738-43. doi: 10.1007/s11655-011-0873-1. Epub 2011 Nov 19.
To study the changes in cardiac function of rheumatoid arthritis (RA) patients and: to observe the effect of xinfeng capsule ( XFC) on them.
Sixty-eight RA patients were: randomly assigned to two groups by a lottery: 38 patients in the treatment group treated orally with XFC, 3 capsules, thrice a day, and 30 in the control group treated with fengshi gutong capsule (FSGTC), 4 capsules, twice a day, 30 days as one course of treatment, and two courses were given for both groups. A normal control (NC) group including 20 healthy subjects was set up. The clinical efficacy was compared between the two treated groups. The changes in cardiac function, including early diastolic peak flow velocity (E), late diastolic peak flow velocity (A), left ventricular fraction shortening (FS), and E/A, as well as uric acid (UA), erythrocyte sedimentation rate (ESR), α-acid glycoprotein (α-AGP), and hypersensitive C-reaction protein (hs-CRP), were observed. The regulation T cell was determined with flow cytometry.
(1) The total effective rate in the treatment group and the control group was 92.1%: (35/38) and 70.0% (21/30), respectively. Significant difference was shown between them (P<0.05). (2) <Compared with those of the NC group, E peak, E/A ratio, and FS of RA patients were lower (P<0.01), while <A peak was higher (P<0.01). Moreover, A peak of the treatment group after treatment was significantly lower <(P<0.05) and E/A ratio was significantly higher (<P<0.05) as compared with those of the control group. (3) The <improvement in the treatment group in reducing UA and hs-CRP was superior to those of the control group (P<0.05). In addition, the improvement in α-AGP, CD4 <CD4(+)CD25 CD25(+) Treg, and CD4 CD4(+)CD25 CD25(+)CD127 CD127(-)Treg of the treatment group was obvious as compared with the control group, although the difference was not statistically significant.
The descendent of cardiac function exists in RA patients. XFC could improve cardiac: function of RA patients, which is superior to FSGTC. Its mechanism may be related to its effect on raising CD4 CD4(+)CD25 CD25(+)Treg and CD4 CD4(+)CD25 CD25(+)CD127(-) Treg cells, decreasing UA, α-AGP, and hs-CRP levels, reducing immune inflammation, adjusting the overall balance of immune response, and thus improving the cardiac function of RA patients.
研究类风湿关节炎（RA）患者心脏功能的变化，并观察新风胶囊（XFC）对其的影响。
将 68 例 RA 患者随机分为两组，每组 38 例。治疗组口服 XFC，每次 3 粒，每日 3 次；对照组口服风湿骨痛胶囊（FSGTC），每次 4 粒，每日 2 次。两组均 30 天为 1 个疗程，共 2 个疗程。设正常对照组（NC 组）20 例。比较两组的临床疗效。观察心脏功能的变化，包括舒张早期峰值流速（E）、舒张晚期峰值流速（A）、左室短轴缩短率（FS）和 E/A 比值，以及尿酸（UA）、红细胞沉降率（ESR）、α-酸性糖蛋白（α-AGP）和超敏 C 反应蛋白（hs-CRP）。采用流式细胞术检测调节性 T 细胞。
（1）治疗组和对照组的总有效率分别为 92.1%（35/38）和 70.0%（21/30），两组比较差异有统计学意义（P<0.05）。（2）与 NC 组比较，RA 患者的 E 峰、E/A 比值和 FS 均降低（P<0.01），A 峰升高（P<0.01）；治疗组治疗后 A 峰明显低于对照组（P<0.05），E/A 比值明显高于对照组（P<0.05）。（3）治疗组降低 UA 和 hs-CRP 的效果优于对照组（P<0.05）。此外，治疗组的α-AGP、CD4+CD25+CD25+Treg、CD4+CD25+CD25+CD127-Treg 的改善明显优于对照组，尽管差异无统计学意义。
RA 患者存在心脏功能下降。XFC 可改善 RA 患者的心脏功能，优于 FSGTC。其机制可能与其提高 CD4+CD25+CD25+Treg 和 CD4+CD25+CD25+CD127-Treg 细胞、降低 UA、α-AGP、hs-CRP 水平、减轻免疫炎症、调节免疫反应整体平衡从而改善 RA 患者心脏功能有关。
